Evidence map›Paper›PMID 18773115›Full record

ArticlePLoS pathogens2008

Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness.

Luke Uebelhoer, Jin-Hwan Han, Benoit Callendret, Guaniri Mateu, Naglaa H Shoukry, Holly L Hanson, Charles M Rice, Christopher M Walker, Arash Grakoui

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. CD8Frontiers in immunology · 2022
    Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. The Role of ApoE in HCV Infection and Comorbidity.International journal of molecular sciences · 2019
    Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Celiac disease and hepatitis C relationships in transcriptional regulatory networks.Gastroenterology and hepatology from bed to bench · 2017
    Article
  18. Review
  19. Status of hepatitis C virus vaccination: Recent update.World journal of gastroenterology · 2016
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Luke UebelhoerDepartment of Medicine, Division of Infectious Diseases, Microbiology and Immunology, Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Jin-Hwan Han
Benoit Callendret
Guaniri Mateu
Naglaa H Shoukry
Holly L Hanson
Charles M Rice
Christopher M Walker
Arash Grakoui
Emory University · USRockefeller University · USCentre Hospitalier de l’Université de Montréal · CANationwide Children's Hospital · USThe Ohio State University · US

Funding

YNPRC NHP CLINICAL MEDICINE RESIDENCY PROGRAM - SUPPLEMENTP51RR000165 · NCRR · EMORY UNIVERSITY · PI JOHNS, MICHAEL M · 1985 to 2011
$114.0M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Hannah LF Cooper · 2002 to 2026
$74.0M
Virus specific T cells in replication/evolution of HCVU19AI048231 · NIAID · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI WALKER, CHRISTOPHER M. · 2000 to 2009
$10.1M
HCV-specific T cell responseR37AI047367 · NIAID · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI WALKER, CHRISTOPHER M. · 2005 to 2014
$6.1M
Mechanisms of hepatitis C virus persistenceR01AI070101 · NIAID · EMORY UNIVERSITY · PI GRAKOUI, ARASH · 2006 to 2016
$3.9M
IMMUNOTHERAPY PROTECTION &VACCINES FOR HEPATITIS CR01CA085883 · NCI · WASHINGTON UNIVERSITY · PI RICE, CHARLES M. · 1999 to 2003
$1.4M
Mechanisms of hepatitis C virus persistenceR56AI070101 · NIAID · EMORY UNIVERSITY · PI GRAKOUI, ARASH · 2011 to 2011
$437k
NCI NIH HHS CA85883NCI NIH HHS R01 CA085883NCRR NIH HHS P51 RR000165NCRR NIH HHS RR-00165NIAID NIH HHS AI070101NIAID NIH HHS N01 AI040034NIAID NIH HHS P30 AI050409NIAID NIH HHS R01 AI070101NIAID NIH HHS R37 AI047367NIAID NIH HHS R37 AI47367NIAID NIH HHS R56 AI070101NIAID NIH HHS U19 AI048231NIAID NIH HHS U19 AI48231
6 · The paper itself

Abstract

Mechanisms by which hepatitis C virus (HCV) evades cellular immunity to establish persistence in chronically infected individuals are not clear. Mutations in human leukocyte antigen (HLA) class I-restricted epitopes targeted by CD8(+) T cells are associated with persistence, but the extent to which these mutations affect viral fitness is not fully understood. Previous work showed that the HCV quasispecies in a persistently infected chimpanzee accumulated multiple mutations in numerous class I epitopes over a period of 7 years. During the acute phase of infection, one representative epitope in the C-terminal region of the NS3/4A helicase, NS3(1629-1637), displayed multiple serial amino acid substitutions in major histocompatibility complex (MHC) anchor and T cell receptor (TCR) contact residues. Only one of these amino acid substitutions at position 9 (P9) of the epitope was stable in the quasispecies. We therefore assessed the effect of each mutation observed during in vivo infection on viral fitness and T cell responses using an HCV subgenomic replicon system and a recently developed in vitro infectious virus cell culture model. Mutation of a position 7 (P7) TCR-contact residue, I1635T, expectedly ablated the T cell response without affecting viral RNA replication or virion production. In contrast, two mutations at the P9 MHC-anchor residue abrogated antigen-specific T cell responses, but additionally decreased viral RNA replication and virion production. The first escape mutation, L1637P, detected in vivo only transiently at 3 mo after infection, decreased viral production, and reverted to the parental sequence in vitro. The second P9 variant, L1637S, which was stable in vivo through 7 years of follow-up, evaded the antigen-specific T cell response and did not revert in vitro despite being less optimal in virion production compared to the parental virus. These studies suggest that HCV escape mutants emerging early in infection are not necessarily stable, but are eventually replaced with variants that achieve a balance between immune evasion and fitness for replication.

Indexed as

MutationCell Line, TumorHepacivirusHumansImmunity, CellularSelection, GeneticT-Lymphocytes, CytotoxicVirus Replication

Identifiers

PMID18773115
PMCPMC2518852
OpenAlexW2030917262

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.